Swanson, Robert

Swanson, Robert S., Plastics Technology, McKnight McKnight Pub. Co. 

Genentech was founded in 1976 by scientist Herbert Boyer and the venture capitalist Robert Swanson. Headquartered in San Francisco, it employs almost 5000 staff worldwide and has 10 protein-based products on the market. These include hGHs (Nutropin, Chapter 11), the anti-body-based products Herceptin and Rituxan (Chapter 13) and the thrombolytic agents Ac-tivase and TNKase (Chapter 12). The company also has 20 or so products in clinical trials. In 2004, it generated some US 4.6 billion in revenues. 

Decker MW, Anderson DJ, Brioni ID, DonneUy-Roberts DL, Kang CH, O Neill AB, Piattoni-Kaplan M, Swanson S, SuUivan IP (1995) Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors, Eur J Pharmacol 280 79-89 Dekeyne A, Girardon S, MUlan Ml (1999) Discriminative stimulus properties of the novel serotonin (5-HT)2c receptor agonist, Ro 60-0175 a pharmacological analysis. Neuropharmacology 38 415-423... 

Robert A. Swanson and biochemist Dr Herbert W. Boyer, and the changes in state and federal laws (the 1980 Bayh-Dole Act) paved the way for universities and academicians to participate in fostering business alliances and creating new companies. 

Swanson, J., Kinsbourne, M., Roberts, W, and Zucker, K. (1978) Time-response analysis of the effect of stimulant medication on... 

The age of biotechnology started in the USA with the foundation of the first biotech company. Genentech was founded by the renowned biochemist Herbert Boyer and the young visionary venture capitalist Robert Swanson. (Of the... 

It has now been more than fifteen years since Robert Swanson, a young man who understood both finance and science, invited Herbert Boyer, a shy molecular biologist at the University of California, San Francisco, out for a beer. Swanson described his vision to Boyer that the techniques and ideas that Boyer had devised... 

Genentech, Inc. was founded in by venture capitalist Robert A. Swanson and biochemist Dr. Heibert W. Boyer. In the early 1970s, Boyer and geneticist Stanley Colien pioneered a new scientific field called recombinant DNA technology. 

With several other proteins, such as bovine serum albiunin (Tanford and Roberts, 1952), lysozyme (Tanford and Wagner, 1954), and/3-lacto-globulin (Tanford and Swanson, 1957), pK shifts of the phenolic OH groups of tyrosine residues are observed, but these are of a qualitatively different nature. Thus, the tyrosines of any one of these proteins cannot be readily differentiated into a normal and an abnormal variety, since the spectrophotometric titration data for these proteins are reversible and fall on single smooth curves, in contrast to the situation with RNase. On the other hand, the tyrosine residues of ovalbumin show comparable behavior to the three abnormal tyrosine groups of RNase (Crammer and Neuberger, 1943). About 2 of the total of 9 tyrosine residues appear to titrate normally, but the remainder are not titrated up to pH 12. At pH 13, these anomalous tyrosines become titratable, and this is accompanied by the irreversible denaturation of the ovalbumin molecule. 

Brinkman, Landauer and Swanson, and Doimelly and Roberts made important progress in extending Kramers method to models with several spatial dimensions. For the relatively simple models that were worked out, the major conclusions attained by Kramers do hold well. (A more detailed discussion of this point is given in the next section.)... 

Cortes J, Haydock SF, Roberts GA, Bevitt DJ, Leadlay PF (1990) Nature 348 176 Donadio S, Staver MJ, McAlpine JB, Swanson SJ, Katz L (1991) Science 252 675 Donadio S, Katz L (1992) Gene 111 51... 

In 1976 Herbert Boyer, one of the discoverers of the rDNA technique and a member of the faculty at UCSF, and Robert Swanson, a venture capitalist with MIT degrees in chemistry and business, formed Genentech. As Swanson put it, in terms reminiscent of those of Landau in chemicals, For Genentech, the strategy from the beginning was to be able to make and sell our own products. Therefore we needed not only to generate products but to manufacture them and build the marketing force to sell them. ... 

Wood, W. B., ed. (1988) The Nematode Caenorhahditis elegans, Cold Spring Harbor Lab. Press, Cold Spring Harbor, New York Kenyon, C. (1988) Science 240, 1448-1453 Roberts, L. (1990) Srience 248, 1310-1313 Riddle, D. L., Swanson, M. M., and Albert, P. 

Genetic engineering is the manipulation of an organism s DNA. In 1976, with venture capitalist Robert Swanson, Herbert Boyer founded a company called Genentech to use recombinant DNA technology to produce medicines. In 1978, the company successfully inserted the human insulin gene into E. coli bacteria and then grew them to produce commercial amounts of insulin. 

Recombinant DNA technology would eventually become so omnipresent in discovery research that people would rarely think about it anymore, like Manhattanites going about their jobs oblivious to the technology that made the skyscrapers they work in possible. The license revenues from Boyer s and Cohen s patents would bring over a quarter billion dollars to Stanford. In 1976 the first company to exploit this technology commercially, Genentech, founded by Dr Boyer along with venture capitalist Robert Swanson, would produce revolutionary new medicines, save lives, enrich shareholders, and would eventually come to be seen as a sort of milestone in the history of modern therapeutics. 

Henry Fielding edited by Claude Rawson F. Scott Fitzgerald edited by Ruth Prigozy Flaubert edited by Timothy Unwin E. M. Forster edited by David Bradshaw Benjamin Franklin edited by Carla Mulford Brian Friel edited by Anthony Roche Robert Frost edited by Robert Faggen Gabriel Garcia Marquez edited by Philip Swanson... 

Charles L. Swanson, George F. Fecht, and Robert C. Burr... 

---